Showing results (261-270 of 446) with videos related to

Sort By:
Pageof 45
Pigment Cell & Melanoma Research|November 21, 2017
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenibMatthew J Wongchenko, Antoni Ribas, Brigitte Dréno, et al.
Frontiers in Oncology|June 26, 2023
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanomaSebastian Bauer, James Larkin, F Stephen Hodi, et al.
European Urology|September 8, 2021
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical TrialEdmond M Kwan, Lavinia Spain, Angelyn Anton, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2019
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaSophia Kreft, Anja Gesierich, Thomas Eigentler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2020
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 EraMichele Maio, Omid Hamid, James Larkin, et al.
Clinical Genitourinary Cancer|August 6, 2024
Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study ResultsPaul Nathan, Balaji Venugopal, Jamshed Ali, et al.
Melanoma Research|February 24, 2021
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trialsRoger Olofsson Bagge, Lars Ny, Paolo A Ascierto, et al.
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Pageof 45